Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial

被引：0
|
作者：
David Z. I. Cherney
Bernard Charbonnel
Francesco Cosentino
Samuel Dagogo-Jack
Darren K. McGuire
Richard Pratley
Weichung J. Shih
Robert Frederich
Mario Maldonado
Annpey Pong
Christopher P. Cannon
机构：
[1] University of Toronto,Unit of Cardiology
[2] University of Nantes,Cardiovascular Division, Brigham and Women’s Hospital
[3] Karolinska Institute & Karolinska University Hospital,undefined
[4] University of Tennessee Health Science Center,undefined
[5] University of Texas Southwestern Medical Center,undefined
[6] Parkland Health and Hospital System,undefined
[7] AdventHealth Translational Research Institute,undefined
[8] Rutgers School of Public Health,undefined
[9] Rutgers Cancer Institute of New Jersey,undefined
[10] Pfizer Inc.,undefined
[11] MSD Limited,undefined
[12] Merck & Co.,undefined
[13] Inc.,undefined
[14] Harvard Medical School,undefined
来源：
Diabetologia | 2021年 / 64卷
关键词：
Cardiovascular disease; Diabetic nephropathies; Ertugliflozin; Type 2 diabetes mellitus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1256 / 1267
页数：11
相关论文
共 50 条
  • [1] Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial
    Cherney, David Z. I.
    Charbonnel, Bernard
    Cosentino, Francesco
    Dagogo-Jack, Samuel
    McGuire, Darren K.
    Pratley, Richard
    Shih, Weichung J.
    Frederich, Robert
    Maldonado, Mario
    Pong, Annpey
    Cannon, Christopher P.
    [J]. DIABETOLOGIA, 2021, 64 (06) : 1256 - 1267
  • [2] Ertugliflozin in older patients with type 2 diabetes: an analysis from VERTIS CV
    Pratley, R. E.
    Cannon, C. P.
    Charbonnel, B.
    Cherney, D. Z. I.
    Cosentino, F.
    McGuire, D. K.
    Shih, W. J.
    Essex, M. N.
    Lawrence, D.
    Jones, P. L. S.
    Liu, J.
    Adamsons, I. A.
    Dagogo-Jack, S.
    [J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 30 - 31
  • [3] Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial
    Pratley, Richard E.
    Cannon, Christopher P.
    Cherney, David Z., I
    Cosentino, Francesco
    McGuire, Darren K.
    Essex, Margaret Noyes
    Lawrence, David
    Jones, Philip L. S.
    Liu, Jie
    Adamsons, Ingrid
    Dagogo-Jack, Samuel
    [J]. LANCET HEALTHY LONGEVITY, 2023, 4 (04): : E143 - E154
  • [4] Effects of Ertugliflozin on Kidney Outcomes in Patients With Heart Failure at Baseline in the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS CV) Trial
    Cherney, David Z. I.
    Cosentino, Francesco
    McGuire, Darren K.
    Kolkailah, Ahmed A.
    Dagogo-Jack, Samuel
    Pratley, Richard E.
    Frederich, Robert
    Maldonado, Mario
    Liu, Chih-Chin
    Cannon, Christopher P.
    [J]. KIDNEY INTERNATIONAL REPORTS, 2023, 8 (04): : 746 - 753
  • [5] Mediators of the effect of ertugliflozin on a composite kidney outcome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: analyses from VERTIS CV
    Cherney, D. Z. I.
    Segar, M.
    Pandey, A.
    Cannon, C. P.
    Cosentino, F.
    Dagogo-Jack, S.
    Pratley, R. E.
    Frederich, R.
    Cater, N. B.
    Maldonado, M.
    Liu, J.
    Liu, C. -C.
    Pong, A.
    McGuire, D. K.
    [J]. EUROPEAN HEART JOURNAL, 2021, 42 : 2925 - 2925
  • [6] Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study
    Grunberger, George
    Camp, Sarah
    Johnson, Jeremy
    Huyck, Susan
    Terra, Steven G.
    Mancuso, James P.
    Jiang, Zhi Wei
    Golm, Gregory
    Engel, Samuel S.
    Lauring, Brett
    [J]. DIABETES THERAPY, 2018, 9 (01) : 49 - 66
  • [7] Ertugliflozin in Older Patients with Type 2 Diabetes (T2D): An Analysis from VERTIS CV
    Pratley, Richard E.
    Dagogo-Jack, Samuel
    Charbonnel, Bernard
    Cherney, David
    Cosentino, Francesco
    Mcguire, Darren K.
    Essex, Margaret N.
    Jones, Philip L. S.
    Liu, Jie
    Adamsons, Ingrid A.
    Lawrence, David
    Shih, Weichung J.
    Cannon, Christopher P.
    [J]. DIABETES, 2021, 70
  • [8] Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study
    George Grunberger
    Sarah Camp
    Jeremy Johnson
    Susan Huyck
    Steven G. Terra
    James P. Mancuso
    Zhi Wei Jiang
    Gregory Golm
    Samuel S. Engel
    Brett Lauring
    [J]. Diabetes Therapy, 2018, 9 : 49 - 66
  • [9] Glycaemic efficacy and safety of ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from VERTIS CV
    Dagogo-Jack, S.
    Pratley, R. E.
    Cherney, D. Z. I.
    Charbonnel, B.
    McGuire, D. K.
    Cosentino, F.
    Shih, W. J.
    Liu, J.
    Frederich, R.
    Mancuso, J. P.
    Raji, A.
    Gantz, I.
    [J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 225 - 226
  • [10] Evaluation of cardiovascular and renal outcomes with ertugliflozin: what is the VERdict from the VERTIS-CV trial?
    Cowart, Kevin
    Carris, Nicholas W.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (02) : 163 - 165
12345